ALK and non-small cell lung carcinoma: TP53 mutations are the most common genomic co-alteration in ALK-positive NSCLC, with overall worse prognosis and survival, with preclinical studies testing ixazomib (a proteasome inhibition), which induced apoptosis in previously alectinib resistance cells149.